LSTA

0.87344.02%
CL

Cynthia Louise Flowers

Independent Director

Ms. Cynthia Louise Flowers, MBA, also Known as Schwalm, serves as Chief Executive Officer of Omeza, LLC. She is Independent Non-Executive Director of Hikma Pharmaceuticals PLC from June 01, 2019. She serves as an CEO and Director at Omeza Holdings, Inc. She joined the Hikma Pharmaceuticals PLC on June 01, 2019. She is an Independent Director of G1 Therapeutics, Inc. since June 7, 2018. She has been Independent Director of Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences, Inc.) since November 8, 2018. Ms. Flowers has been an Independent Director of Kadmon Holdings, Inc. since January 23, 2019. Ms. Flowers served as Director at Nanoform Finland Plc since September 01, 2020 until May 20, 2021 and serves as its Senior Advisor to the CEO for Business Development US. She is Director of Kadmon Group. She served as the Chief Executive Officer and President at Ipsen Biopharmaceuticals, Inc. from February 2014 to October 2017. She serves as an Independent Consultant and Owner at EIR Advisory LLC since 2018. She served as President and Chief Executive Officer of Ipsen North America since 2014 until October 2017. She serves as member of the board of directors of Relevate Health since 2021. She served as President of Eisai Pharmaceuticals from 2008 to 2010 and at Amgen, Inc. as Vice President & General Manager of U.S. Oncology from 2005 to 2008 and Executive Director of the U.S. Oncology Business Unit from 2003 to 2005. Ms. Flowers served as an Executive Vice President and President of North American Commercial Operations at Ipsen S.A. since February 2014 and served as its Member of Executive Team since August 26, 2016. She served as Chief Executive Officer of North America and President of North America at Ipsen S.A. from August 20, 2014 to October 2017. She served as Vice President of US Neurosciences at Merz North America, Inc. since September 2012. She leads the neuroscience strategy development and commercial implementation for meeting franchise objectives in the US. Her role acts as a leading conduit between the commercial needs for success in the US and Global Project Teams for assigned neuroscience projects. She has spent her entire career in the healthcare industry. She served as a Vice President of Neurology at Merz, Incorporated since September 17, 2012. She has been instrumental in building commercial capabilities and a talented leadership team in preparation for the launch of its first oncology product in the U.S. in 2015, a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs). She is an industry veteran working in pharmaceuticals, biotechnology and medical devices. Prior to joining Merz, Ms. Flowers was the Senior Advisor to the Chief Executive Officer at Chimerix, Inc. She served as a Senior Vice President of International at Optimer Pharmaceuticals, Inc. since May 3, 2011. Prior to joining Ipsen, she worked in various acting COO and C-suite consulting roles for emerging biotechnology and pharmaceutical companies. Ms. Flowers joined Optimer from Eisai Pharmaceuticals Inc., the U.S. commercial arm of Tokyo-based Eisai Co., Ltd., where she served as President from May 2008 to 2010. Ms. Flowers has senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. Previously, she served as Chief Operating Officer of Eisai Inc. She joined Eisai in 2008 from Amgen Inc. She served as a Vice President and General Manager of the Oncology Business Unit of Amgen Inc. from May 2005 to 2008. She served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory and health economic functions. She served as Senior Director/Executive Director of Marketing in Oncology from May 2003 to May 2005. Ms. Flowers also previously held multiple commercial roles at Johnson & Johnson and Janssen Pharmaceutica, Inc. from 1985 to 2003. Before joining Amgen, she served as Managing Director of Ortho Biotech, Johnson & Johnson's Biotechnology commercial operations unit in the U.K. and Ireland. Ms. Flowers grew her pharmaceutical career over period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. She gained experience in oncology commercialization and also developed sales and marketing expertise in critical care, neurology/analgesia and gastroenterology. Previous to this role, she served as Executive Director of J&J Pharma's Global Franchise Development for the Analgesia and Women's Health Franchises. She has been Independent Non-Executive Director of Hikma Pharmaceuticals PLC since June 1, 2019. Ms. Flowers also serves on the boards of the Sarah Cannon Oncology Research Institute, The Children's Aid and Family Services Organization of Bergen County, NJ and Beth Abrahams Family Services, NYC. She is a member of Harvard JFK School of Public Policy Women's Leadership Board and the International Women's Forum, a merit-based organization of the highest ranking women in business. In April 2009, she was recognized as one of New Jersey's Top 50 Women in Business by NJ Biz. She held various sales and marketing positions in J&J since 1984. She is a member of the National Association of Corporate Directors. She is Member of an angel investment group associated with the University of North Carolina. Ms. Flowers holds a B.S. degree in Nursing from the University of Delaware and an Executive Master of Business Administration from the Wharton School of Business from the University in Pennsylvania in Philadelphia, PA.

Positions